Evidence map›Paper›PMID 41124251›Full record

ArticleScience advances2025

GENRISE-induced superior extracellular vesicles for scalable therapeutic cargo delivery.

Hyejin Kim, Sunghyun Moon, Dajeong Kim, In-Ho Jeong, Eun-Koung An, Hae-Bin Park, Seon-Mi Jin, Yoonbin Ji, Ohsung Ko, Ju Hong Min and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Hyejin KimDepartment of Chemical Engineering, University of Seoul, Seoul 02504, Republic of Korea.ORCID 0000-0002-7937-2733
Sunghyun MoonDepartment of Chemical Engineering, University of Seoul, Seoul 02504, Republic of Korea.ORCID 0009-0004-4830-3630
Dajeong KimDepartment of Chemical Engineering, University of Seoul, Seoul 02504, Republic of Korea.
In-Ho JeongDepartment of Biochemistry and Molecular Biology, Brain Korea 21 project, University of Ulsan College of Medicine, ASAN Medical Center, Seoul 05505, Republic of Korea.ORCID 0009-0001-0416-3937
Eun-Koung AnDepartment of Microbiology, Brain Korea 21 Project, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea.
Hae-Bin ParkDepartment of Microbiology, Brain Korea 21 Project, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea.
Seon-Mi JinSchool of Materials Science and Engineering, Gwangju Institute of Science and Technology (GIST), Gwangju 61005, Republic of Korea.ORCID 0000-0001-5820-4637
Yoonbin JiDepartment of Chemical Engineering, University of Seoul, Seoul 02504, Republic of Korea.ORCID 0009-0005-9213-2303
Ohsung KoDepartment of Chemical Engineering, University of Seoul, Seoul 02504, Republic of Korea.
Ju Hong MinSchool of Materials Science and Engineering, Gwangju Institute of Science and Technology (GIST), Gwangju 61005, Republic of Korea.
Hwankyu LeeDepartment of Chemical Engineering, Dankook University, Yongin-si 16890, Republic of Korea.ORCID 0000-0002-2036-1490
Eunji LeeSchool of Materials Science and Engineering, Gwangju Institute of Science and Technology (GIST), Gwangju 61005, Republic of Korea.ORCID 0000-0001-7494-1776
Young Jik KwonDepartment of Chemical Engineering and Materials Science, University of California, Irvine, CA 92697, USA.ORCID 0000-0003-4086-6995
Jun-O JinDepartment of Microbiology, Brain Korea 21 Project, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea.ORCID 0000-0003-4216-8111
Peter C W LeeDepartment of Biochemistry and Molecular Biology, Brain Korea 21 project, University of Ulsan College of Medicine, ASAN Medical Center, Seoul 05505, Republic of Korea.ORCID 0000-0002-2320-6365
Jong Bum LeeDepartment of Chemical Engineering, University of Seoul, Seoul 02504, Republic of Korea.ORCID 0000-0002-8319-5055

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extracellular vesicles (EVs) demonstrate immense potential as naturally derived carriers of active therapeutics. To maximize their capacity, it is crucial to develop effective methods for manipulating cargo and ensuring scalability. To address this challenge, we propose that protein-free mRNA granule-like structures, named gene-encoded nanoparticle RNA for inducing superior EVs (GENRISE), can function as active translational sponge and as transient subcellular compartments. The overexpression of proteins in proximity to RNA assemblies stimulates parental cells to release excess exogenous proteins in induced superior EVs (iSEVs). The iSEV system enables the single-module-based enrichment of exogenous cargo in EVs with scalable manufacturing. By harnessing mass-produced iSEVs induced by GENRISEs, encoding an antigenic peptide, we have successfully demonstrated target-specific in vivo cancer immunotherapy. These findings suggest that the emerging iSEV platform shows considerable potential for biomedical applications by enabling the controlled production of cargo-specific EVs.

Indexed as

Drug Delivery SystemsExtracellular VesiclesNanoparticlesAnimalsCell Line, TumorHumansImmunotherapyMiceNeoplasmsRNA, MessengerRNA, Messenger

Identifiers

PMID41124251
PMCPMC12542945

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.